Latest Breaking News On - Heavily pretreated patients with - Page 1 : comparemela.com

Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.

United statesYi linThomasg martinCiltacabtagene autoleucelHelen diller family comprehensive cancer centerMeeting of the society hematologic oncologyMayo clinicDiller family comprehensive cancer centerAnnual meetingSociety hematologic oncologyHeavily pretreated patients withRefractory multipleSociety of hematologic oncology annual meeting sohoMultiple myeloma2023 soho annual meetingPhase 1b 2 cartitude 1 study